Atezolizumab in combination with platinum-based chemotherapy for untreated locally advanced or metastatic urothelial cancer – first line

Atezolizumab is in clinical development, in combination with platinum-based chemotherapy, for the treatment of patients with locally advanced or metastatic urothelial cancer, who have received no prior systemic therapy (a drug which travels through the bloodstream and affects the whole body). Urothelial cancer, a subset of bladder cancer, occurs on the lining of the bladder, and other parts of the urinary system. In advanced urothelial cancer, the cancer has grown into deeper layers including connective tissue or muscle. Metastatic urothelial cancer occurs when the cancer has spread to other parts of the body, such as the liver or bones.
Atezolizumab, administered by intravenous infusion, is designed to stimulate the body’s own immune system to fight cancer cells. If licensed, atezolizumab will provide an additional option for the first-line treatment of locally advanced or metastatic urothelial cancer in patients who are both eligible and ineligible for cisplatin chemotherapy.